Apellis Pharmaceuticals (APLS) said Monday that Australia's Therapeutic Goods Administration approved Syfovre for the every-other-month treatment of geographic atrophy in adults with age-related macular degeneration resulting in vision loss.

The decision was supported by 24-month data from phase 3 studies, which showed that both monthly and every-other-month use of the treatment reduced GA progression and was generally well tolerated, the company said.